Alzheimer Drugs Market: Eli Lilly, Eisai & Anti-Amyloid Drugs, Alzheimer's Therapies Growth in United States Expansion

Alzheimer Drugs Market reached US$ 4.46 billion in 2023 and is expected to reach US$ 18.33 billion by 2031, growing at a CAGR of 19.4% during the forecast period 2024-2031.

DataM Intelligence has released its latest "Alzheimer Drugs Market Size 2026" report, delivering comprehensive insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion.

India's Alzheimer's Market Enters a New Treatment Era

• Eli Lilly | Donanemab (Lormalzi): Launched in India in May 2026 for early Alzheimer's; monthly IV dosing at ₹97,000 per 350 mg vial, with trials showing 35% slower cognitive and functional decline.

• Eisai | Lecanemab (Leqembi): Launched in India in August 2026; administered twice monthly for 18 months, priced at ₹21,682 per vial, with studies reporting approximately 27% to 33% slower decline.

• Market & Patients: India had an estimated 8.8 million people aged 60+ living with dementia, projected to reach 16.9 million by 2036 if prevalence remains unchanged.

• Treatment Access: Both anti-amyloid disease-modifying therapies target early Alzheimer's and require biomarker confirmation, making PET/CSF diagnostic capacity and treatment infrastructure critical to wider adoption.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/alzheimer-drugs-market?kb

United States: Recent Industry Developments

✅ July 2026: Eisai and Biogen received FDA approval for LEQEMBI IQLIK (lecanemab) as a once-weekly subcutaneous initiation dose for early Alzheimer's disease, enabling at-home administration.

✅ July 2026: Biogen presented Phase 2 CELIA data for diranersen, showing meaningful clinical outcomes and robust reductions in tau biomarkers in early Alzheimer's disease, with plans to advance the therapy into Phase 3.

✅ June 2026: Eisai announced plans to present 52 Alzheimer's disease research abstracts at AAIC 2026, covering lecanemab and the investigational anti-tau therapy etalanetug.

✅ January 2026: Eisai and Biogen announced FDA acceptance of the supplemental application for LEQEMBI IQLIK as a weekly subcutaneous starting dose under Priority Review.

Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/alzheimer-drugs-market?kb

1. LM11A-31 Targets Alzheimer's Beyond Amyloid

• PharmatrophiX: LM11A-31 targets p75NTR, focusing on synaptic protection and brain-network function rather than directly clearing amyloid.

• Phase 2a: The randomized trial included 242 patients with mild-to-moderate Alzheimer's over 26 weeks, testing 200 mg and 400 mg doses.

• Imaging: FDG-PET analysis of 159 participants showed dose-dependent improvements in whole-brain connectivity and efficiency.

• Next step: PharmatrophiX plans a Phase 2b/3 trial, positioning LM11A-31 as a potential complementary approach to anti-amyloid therapies.

Top List of Key Player:

F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, Lupin, Siemens Healthineers and AbbVie.

Key Industry Developments 2026:

✅ July 2026: Eisai and Biogen received U.S. FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous lecanemab formulation that provides an alternative to intravenous administration for patients with early Alzheimer's disease.

✅ June 2026: Voyager Therapeutics received FDA clearance for the IND application for VY1706, an investigational gene therapy designed to reduce intracellular and extracellular tau in Alzheimer's disease, with clinical dosing expected to begin in the second half of 2026.

✅ May 2026: Roche, in collaboration with Eli Lilly, received CE Mark approval for the Elecsys pTau217 blood test, designed to help detect Alzheimer's pathology through a minimally invasive blood-based assessment.

✅ January 2026: Novartis and SciNeuro Pharmaceuticals entered a licensing agreement valued at up to US$1.7 billion to develop antibody-based Alzheimer's treatments, including SciNeuro's technology designed to improve antibody delivery across the blood brain barrier.

✅ October 2025: NeuroSense Therapeutics reported positive Phase 2b findings for PrimeC, with statistically significant reductions in several Alzheimer's disease-associated microRNAs linked to neuroinflammatory and neurodegenerative activity.

How Our Market Research Process Works 2026-2033:

The Alzheimer Drugs Market report by DataM Intelligence delivers comprehensive insights backed by extensive primary and secondary research. It analyzes key market trends, competitive dynamics, regulatory developments, technological advancements, emerging innovations, and growth opportunities while highlighting potential challenges and evolving market conditions. The report provides actionable intelligence to support strategic planning and identify future market potential.

2. Suvorexant Opens a Sleep-Based Alzheimer's Research Path

• Drug: Suvorexant, an insomnia medication, was studied for its potential effect on Alzheimer's-associated amyloid and tau proteins.

• Study: 38 cognitively healthy middle-aged participants received treatment for only 2 consecutive nights.

• Finding: Researchers observed a modest reduction in amyloid and tau-related proteins, supporting further investigation of sleep pathways.

• Development stage: The findings remain early clinical research, with no evidence yet that suvorexant prevents or slows Alzheimer's disease.

Latest M & A/ partnerships in 2026:

• June 10, 2026: Eli Lilly entered an Alzheimer's drug development deal with AlzeCure Pharma worth more than US$1 billion, including US$10 million upfront, plus development and commercial milestones and tiered royalties for AlzeCure's gamma-secretase modulator program.

• July 1, 2026: QuantumCell signed a global licensing and collaboration agreement with AlzeCure Pharma for its NeuroRestore Alzheimer's platform, including ACD856, with total milestone payments exceeding US$2.2 billion; the upfront payment was US$12 million, including a US$5 million investment in AlzeCure.

Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=alzheimer-drugs-market?kb

Japan: Recent Industry Developments

✅ July 2026: Eisai presented new findings on etalanetug (E2814) showing reductions in the Alzheimer's disease tau biomarker MTBR-tau243, supporting continued development of the investigational anti-tau therapy.

✅ June 2026: Japan's PMDA issued an investigation summary for lecanemab, including updated precautions concerning amyloid-related imaging abnormalities (ARIA) and recommended clinical evaluation, including MRI, when ARIA is suspected.

✅ March 2026: An interim Japanese post-marketing surveillance analysis of lecanemab in early Alzheimer's disease provided real-world treatment data from patients in Japan, supporting continued assessment of its clinical use.

✅ January 2026: Eisai and Biogen advanced the U.S. regulatory review of LEQEMBI IQLIK, while Japan continued regulatory development of the subcutaneous formulation following its November 2025 submission.

Key Segmentation Plannings (2026):

By Drugs Type: Donepezil, Galantamine, Rivastigmine, Memantine, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Sales

3. ETH Zurich's Compound 10 Targets a New Alzheimer's Pathway

• ETH Zurich: Researchers identified GRK2 as a potential Alzheimer's target after studying human brain tissue and Alzheimer's mouse models.

• Drug candidate: Experimental Compound 10 prevented inactive GRK2 aggregation and improved mitochondrial function in preclinical studies.

• Preclinical value: Treatment reduced amyloid-beta accumulation and nerve-cell damage in mice, while also showing effects on heart function and aging markers.

• Next stage: Compound 10 has not entered human clinical trials; ETH Zurich is seeking a company partner to advance development.

Global Market Growth Regional Analysis:

⇥ North America: The region holds a strong position in the Alzheimer Drugs Market, supported by advanced healthcare infrastructure, greater access to neurological care, and the availability of innovative Alzheimer's therapies.

⇥ Europe: The market is supported by increasing investment in dementia research, improved diagnosis, and growing access to disease-modifying and symptomatic Alzheimer's treatments.

⇥ Asia-Pacific: The region is witnessing increasing adoption of Alzheimer drugs due to its aging population, improving healthcare infrastructure, and greater awareness of cognitive disorders.

⇥ Latin America: Market development is supported by improving access to healthcare services, rising awareness of Alzheimer's disease, and gradual improvements in diagnosis and treatment.

⇥ Middle East & Africa: The market is developing alongside improvements in neurological healthcare services, diagnostic capabilities, and awareness of Alzheimer's disease among healthcare professionals and patients.

4. Alzheimer's Drug Development Expands Beyond Amyloid

• Innovation: The three approaches target different mechanisms: p75NTR, sleep-related pathways and GRK2, highlighting diversification beyond conventional amyloid therapies.

• Clinical pipeline: LM11A-31 is the most advanced, with Phase 2a data supporting planned Phase 2b/3 development, while Compound 10 remains preclinical.

• Regions: Research spans U.S. institutions including PharmatrophiX, Stanford and Indiana University, alongside ETH Zurich in Switzerland.

• Strategic outlook: These programs could potentially complement existing lecanemab and donanemab therapies if longer clinical studies confirm meaningful cognitive benefits.

Request a Customized Market Report Today:- https://www.datamintelligence.com/customize/alzheimer-drugs-market?kb

Market Drivers

• Growing Alzheimer's patient population - An estimated 7.4 million Americans aged 65+ are living with Alzheimer's in 2026, creating a substantial treatment base.

• Advances in disease-modifying therapies - New anti-amyloid treatments such as lecanemab and donanemab are shifting treatment toward therapies designed to slow disease progression.

• Greater focus on early diagnosis - Improved amyloid and tau imaging, along with blood-based biomarkers, are supporting earlier identification of patients who may benefit from treatment.

• New treatment access in emerging markets - LEQEMBI (lecanemab) launched in India in August 2026 for early Alzheimer's disease, broadening access to disease-modifying treatment.

FAQ's

Q1: What is the current market size of the Alzheimer Drugs Market and its future outlook?

Ans: The global Alzheimer Drugs Market reached US$ 4.46 billion in 2023 and is forecast to attain US$ 18.33 billion by 2031

Q2: How fast is the Alzheimer Drugs Market expected to grow during the forecast period?

Ans: The market is projected to expand at a CAGR of 19.4% from 2024 to 2031, reflecting strong growth potential over the forecast period.

Q3: Which region leads the Alzheimer Drugs Market?

Ans: North America accounted for the largest market share, contributing 39.1% in 2022

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.